SEC Tracker
Get the app

Nika Pharmaceuticals NIKA

Nika Pharmaceuticals reported $0 revenue and a $13,023 net loss for Q3 2026.

Nika Pharmaceuticals (NIKA) filed a 10-Q with the SEC on Nov 10, 2026, 8:58 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $13,023 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $352 as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“These factors raise substantial doubt about its ability to continue as a going concern.”
Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 10, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Nika Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange QoQ
Operating income and margin−$13K−$20K+34%
Net income−$13K−$20K+34%
Operating cash flow−$11K−$8K−44%
Cash$352$3K−88%

Data on this page was fetched . The filing on SEC.gov is the record.